KTTA on Nasdaq

Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is an American pharmaceutical preparations company based in Miami Beach.1 Its shares trade on Nasdaq under the symbol KTTA.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with Catabasis Pharmaceuticals, DiaMedica Therapeutics Inc. or EXICURE, INC., or pick any stock.

  • TickerKTTA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersMiami Beach, Florida1
  • Incorporated inDE2
  • Business address1111 Lincoln Road, Suite 500, Miami Beach, Fl 331392
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Recent findings implicate C4A in synaptic loss (fewer connections between nerve cells), which has been shown to occur in schizophrenia.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-2587.3%Operating margin4
-2864.3%Net margin4
3130.4%Revenue growth, 20225
-32.8%Return on equity6
-$14.7MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue1¢$113.2K
  • Research and development21¢$2.7M
  • Selling, general and admin78¢$9.9M
  • Interest0¢$102

Out of $486.6K in revenue.54 The company lost money this year.

Financial statements

Revenue5$486.6K in 2022+3130% since 2021
0$200.0K$400.0K$600.0K2021: $15.1K$15.1K20212022: $486.6K$486.6K2022+3130%
Operating income54-$12.6M in 2022+179% since 2021
-$15.0M-$10.0M-$5.0M02021: -$4.5M-$4.5M20212022: -$12.6M-$12.6M2022+179%
Net income54-$13.9M in 2022+541% since 2021
-$15.0M-$10.0M-$5.0M02021: -$2.2M-$2.2M20212022: -$13.9M-$13.9M2022+541%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
General and administrative$12.9M$7.1M
Research and development$8.0M$7.2M
Loss from operations-$20.9M-$14.2M
Change in fair value of warrant liabilities$115.3K-$77.8K
Realized foreign currency translation loss from dissolution of subsidiaries-$7.2K
Foreign currency gain$30.4K
Other income$380.5K
Change in fair value of derivative warrant liability-$416.6K
Interest and dividends, net$327.2K$423.2K
Other income, net$429.6K$345.4K
Loss before income taxes-$20.4M-$13.9M
Net loss-$20.4M-$13.9M
Weighted-average common shares outstanding, basic (in Shares)7.0M shares1.1M shares
Weighted-average common shares outstanding, diluted (in Shares)7.0M shares1.1M shares
Basic loss per share (in Dollars per share)-$2.91-$12.69
Diluted loss per share (in Dollars per share)-$2.91-$12.69
Foreign currency translation$18.8K-$2.5K
Comprehensive loss-$20.4M-$13.9M

Compare Pasithea Therapeutics Corp. with another company

Corporate structure

Pasithea Therapeutics Corp. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Pasithea Therapeutics Corp.

  • Vivo Opportunity Fund Holdings, L.P. Filed SCHEDULE 13G/A on Pasithea Therapeutics Corp., latest Aug 14, 2026 (2 filings since Dec 5, 2025)
  • Opaleye Management Inc. Filed SCHEDULE 13G/A on Pasithea Therapeutics Corp., latest Jul 31, 2026 (2 filings since Apr 8, 2026)
  • Coastlands Capital LP Filed SCHEDULE 13G/A on Pasithea Therapeutics Corp., latest Jul 1, 2026 (2 filings since Feb 27, 2026)
  • Stonepine Capital Management, LLC Filed SCHEDULE 13G on Pasithea Therapeutics Corp., latest Jun 23, 2026
  • Funicular Funds, LP Filed SCHEDULE 13G on Pasithea Therapeutics Corp., latest Apr 22, 2026
  • CVI Investments, Inc. Filed SCHEDULE 13G/A on Pasithea Therapeutics Corp., latest Feb 17, 2026 (3 filings since May 12, 2025)
  • Squadron Capital Management LLC Filed SCHEDULE 13G/A on Pasithea Therapeutics Corp., latest Feb 17, 2026 (2 filings since Dec 5, 2025)
  • Adage Capital Management, L.P. Filed SCHEDULE 13G on Pasithea Therapeutics Corp., latest Feb 12, 2026
  • Janus Henderson Group Ltd. Filed SCHEDULE 13G on Pasithea Therapeutics Corp., latest Dec 8, 2025
  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Pasithea Therapeutics Corp., latest May 15, 2025 (3 filings since Nov 14, 2024)
  • INTRACOASTAL CAPITAL, LLC Filed SCHEDULE 13G on Pasithea Therapeutics Corp., latest May 12, 2025
  • Orca Capital AG Filed SCHEDULE 13G/A on Pasithea Therapeutics Corp., latest May 9, 2025 (2 filings since May 9, 2025)
  • Pasithea Therapeutics Corp. Miami Beach, Florida

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Pasithea Therapeutics Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$164.7K10 Dec 31, 2024$164.7K6 Dec 31, 20230%
Accumulated depreciation$42.4K10 Dec 31, 2024$23.5K6 Dec 31, 2023+80.3%
Property and equipment, net$122.3K10 Dec 31, 2024$141.2K6 Dec 31, 2023−13.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$55.2M10 Dec 31, 2025$6.9M10 Dec 31, 2024+696.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.3M10 Dec 31, 2024$1.3M6 Dec 31, 20230%
Intangible assets, net (excluding goodwill)$2.9M10 Dec 31, 2025$7.3M6 Dec 31, 2024−60.3%
Finite-lived intangibles, gross$8.6M10 Dec 31, 2025$8.6M10 Dec 31, 20240%
Accumulated amortization-$1.9M10 Dec 31, 2025-$1.3M10 Dec 31, 2024−50.0%
Finite-lived intangibles, net$3.8M10 Dec 31, 2025$7.3M10 Dec 31, 2024−48.3%

Properties, in its own words

We do not own any real property.

Our principal executive office is located at 1111 Lincoln Road, Suite 500, Miami Beach, FL 33139. We rent approximately 300 square feet of space, which includes our executive offices.

The rest of Item 2

We believe that our facilities are generally in good condition and suitable to operate our business. We also believe that, if required, suitable alternative or additional space will be available to us on commercially reasonable terms.

Item 2 of the 10-K filed Mar 30, 2026.3

Leadership

Who has led Pasithea Therapeutics Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Tiago Marques2021–now

Chief financial officer

  1. Stanley Gloss2021
  2. Daniel H. Schneiderman2022–now

Chief operating officer

  1. Yassine Bendiabdallah2021
2025
Board members and other officers (9)

Timeline

  1. Sep 16, 20268-K Other events22
  2. Sep 9, 20268-K Shareholder vote23
  3. Aug 21, 20268-K Listing notice or transfer24
  4. May 4, 20268-K Executive or director change; Regulation FD disclosure25
  5. Feb 20, 20268-K Listing notice or transfer26
  6. Jan 28, 20268-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote27
  7. Dec 15, 20258-K Other events28
  8. Dec 2, 20258-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure29
  9. Nov 25, 20258-K Regulation FD disclosure; Other events30
  10. Nov 4, 20258-K Regulation FD disclosure; Other events31
  11. Oct 27, 20258-K Executive or director change32
  12. Sep 16, 20258-K Regulation FD disclosure; Other events33
  13. Sep 14, 2021New chief executive Tiago Marques becomes CEO11

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.41) a share, on Nov 13, 2025.34

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

306 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 44 major events, 71 insider forms, 44 large holders, 1 private raises, 124 other. The latest 20:

  1. Sep 16, 202625-NSE EDGAR
  2. Sep 16, 20268-K CURRENT REPORT EDGAR
  3. Sep 9, 20268-K CURRENT REPORT EDGAR
  4. Aug 21, 20268-K CURRENT REPORT EDGAR
  5. Aug 14, 202610-Q QUARTERLY REPORT EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 7, 2026ARS EDGAR
  8. Aug 7, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
  9. Jul 31, 2026SCHEDULE 13G/A EDGAR
  10. Jul 29, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
  11. Jul 1, 2026SCHEDULE 13G/A EDGAR
  12. Jun 23, 2026SCHEDULE 13G EDGAR
  13. Jun 22, 20264 OWNERSHIP DOCUMENT EDGAR
  14. May 15, 202610-Q QUARTERLY REPORT EDGAR
  15. May 15, 2026SCHEDULE 13G/A EDGAR
  16. May 5, 20264 EDGAR
  17. May 5, 20264 EDGAR
  18. May 5, 20264 EDGAR
  19. May 5, 20264 EDGAR
  20. May 5, 20264 EDGAR

The 306 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

16 open-market trades by officers, directors and large owners since October 2021: 15 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 17, 2026Coastlands Capital LP10% ownerBuy100,000$0.53$53.0KForm 4
Nov 28, 2025STEINMAN LAWRENCEDirectorBuy133,333$0.75$100.0KForm 4
Nov 28, 2025Marques TiagoChief Executive OfficerBuy33,333$0.75$25.0KForm 4
Nov 28, 2025Dumesnil SimonDirectorBuy33,333$0.75$25.0KForm 4
May 12, 2025Marques TiagoChief Executive OfficerSale960$0.83$797Form 4
Jun 2, 2023STEINMAN LAWRENCEDirectorBuy30,000$0.43$12.9KForm 4
Oct 17, 2022Delaney DavidBuy1,000$1.11$1.1KForm 4
Sep 29, 2022Camac Fund, LPBuy6,710$1.16$7.8KForm 4
Sep 28, 2022Camac Fund, LPBuy57,647$1.19$68.6KForm 4
Sep 6, 2022Camac Fund, LPBuy21,748$1.13$24.6KForm 4
Sep 2, 2022Camac Fund, LPBuy11,507$1.14$13.1KForm 4
Sep 1, 2022Camac Fund, LPBuy55,646$1.13$62.9KForm 4
Aug 30, 2022Camac Capital, LLCBuy17,828$1.15$20.5KForm 4
Aug 29, 2022Camac Capital, LLCBuy5,000$1.17$5.8KForm 4
Aug 19, 2022Leonite Capital LLCBuy54,644$1.30$71.0KForm 4
Aug 17, 2022Camac Fund, LPBuy155,773$1.21$188.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Tiago Reis Marques49$533.6K$1.3M54
2025Daniel Schneiderman48$387.0K$895.2K54
2024Chief Executive Officer$450.0K$640.1K54
2024Chief Development Officer$386.5K$434.8K54
2024Chief Financial Officer$330.0K$430.2K54

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 29, 2021Raised $30.4 million in a private offering of equity Form D: 21 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Cable Car Capital, LP3,000,000$1.5M0.0%+1,793,621
Stonepine Capital Management, LLC2,201,468$1.1M0.9%+1,370,167
Jupiter Topco LLC2,100,000$1.1M0.0%New
Adage Capital Partners Gp, L.l.c.2,100,000$1.1M0.0%No change
Opaleye Management Inc.2,050,000$1.1M0.1%New
Ameriprise Financial Inc1,864,485$961.0K0.0%+513,589
Squadron Capital Management LLC1,000,000$515.4K0.2%−1,100,000
AdvisorShares Investments LLC937,550$483.2K0.1%+600,042
Vivo Capital, LLC465,471$239.9K0.0%−1,634,529
Persistent Asset Partners Ltd290,555$149.8K0.0%No change
UBS Group AG188,111$96.9K0.0%+161,962
XTX Topco Ltd127,572$65.8K0.0%+93,821
Vanguard Capital Management LLC126,279$65.0K0.0%+72,464
Geode Capital Management, LLC83,856$43.2K0.0%−20,129
Renaissance Technologies LLC65,600$33.8K0.0%−27,799
Two Sigma Investments, LP64,166$33.1K0.0%+43,112
Vanguard Fiduciary Trust Co43,860$22.6K0.0%No change
Northern Trust Corp31,405$16.2K0.0%+12,033
Jump Financial, LLC29,363$15.1K0.0%New
Tower Research Capital LLC (TRC)8,838$4.6K0.0%+6,984
Hurley Capital, LLC7,000$3.6K0.0%+3,311
SBI Securities Co., Ltd.1,051$5420.0%No change
Barclays PLC269$1390.0%New
Jpmorgan Chase & Co150$790.0%No change
Royal Bank Of Canada275$00.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Pasithea Therapeutics Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPasithea Therapeutics Corp.1
  • CIK0001841330
  • Employer ID (EIN)85-15919633
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1111 Lincoln Road, Suite 500, Miami Beach, FL 331391
  • Phone(702) 514-41741
  • Shares outstanding33,414,448 as of Aug 12, 20269
  • Public float$5.1M as of Jun 30, 20253
  • AuditorCBIZ CPAs P.C., Hartford, Connecticut PCAOB ID 199; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJan 29, 20211
  • Filings343 in all: 4 (50), 8-K (41), CORRESP (24), 3 (19), 10-Q (15), UPLOAD (14), SCHEDULE 13G (12), 424B3 (11)1
    All 50 form types

    DEFA14A (10), SCHEDULE 13G/A (10), DFAN14A (9), EFFECT (9), SC 13D/A (9), 4/A (8), S-1/A (7), DEF 14A (6), PRE 14A (6), SC 13G (6), 10-K (5), S-8 (5), SC 13G/A (5), ARS (4), DEFC14A (4), PREC14A (4), S-1 (4), SC TO-I/A (4), 3/A (3), 424B4 (3), 8-K/A (3), D (3), FWP (3), S-3 (3), 10-K/A (2), 424B5 (2), DRS (2), POS AM (2), PRRN14A (2), SC 13D (2), 144 (1), 25-NSE (1), 8-A12B (1), CERT (1), DEL AM (1), DRSLTR (1), NT 10-Q (1), PRER14A (1), S-1MEF (1), SC TO-C (1), SC TO-I (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Aug 7, 2026
    Latest 8-K (8-K) Sep 16, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareKTTANasdaq
Warrants to purchase shares of Common Stock, par value $0.0001 per shareKTTAWNasdaq

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Pasithea Therapeutics Corp. names in Item 1A of its 10-K filed Mar 30, 2026: 43 risks under these headings, as written.3

  • Risks Related to Our Financial Position and Need for Additional Capital
  • We have a limited operating history and have no products or services approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.
  • We have a history of losses and may not be able to achieve profitability going forward.
  • We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our drugs.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Changes in U.S. tax law may materially adversely affect our financial condition, results of operations and cash flows.
  • Our ability to use our net operating losses and other tax attributes may be limited.
  • Unfavorable global economic conditions and adverse developments with respect to financial institutions and associated liquidity risk could adversely affect our business, financial condition and stock price.
  • Risks Related to Development, Clinical Testing, Manufacturing, Regulatory Approval and Commercialization
  • Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.
  • Our industry is subject to extensive regulatory obligations and policies that may be subject to change, including due to judicial challenges.
  • Our choice of product candidates and our development plans for our product candidates are subject to change based on a variety of factors, some of which may be out of our control, and if we abandon development of a product candidate we may not be able to develop or acquire a replacement product candidate.
The other 32 risks
  • The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
  • Approval may be delayed or denied because we cannot satisfy the FDA’s Chemistry, Manufacturing and Control Requirements.
  • We may encounter substantial delays in our planned clinical trials or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.
  • We conduct certain of our clinical trials for our product candidates outside of the U.S. which, among other risks, exposes us to the possibility that the FDA and other comparable foreign regulatory authorities may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.
  • Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.
  • We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through an expedited review program, and if we are unable to do so, then we could face increased expense to obtain, and delays in the receipt of necessary marketing approvals.
  • We may seek Orphan Drug Designation for our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity.
  • If any of our product candidates are approved for marketing and commercialization and we have not developed or secured third-party marketing, sales and distribution capabilities, we will be unable to successfully commercialize such products and may not be able to generate product revenue.
  • The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting pre-approval promotion and the promotion of off-label uses.
  • Our business activities may be subject to the U.S. Foreign Corrupt Practices Act, or the FCPA, and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.
  • Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.
  • Disruptions in the global economy and supply chains may have a material adverse effect on our business, financial condition and results of operations.
  • Pursuant to the AlloMek Agreement, the AlloMek Sellers have a right to repurchase certain assets and specified intellectual property from us in the event of a change of control and if we fail to meet certain obligations regarding development and commercialization.
  • Risks Related to Our Dependence on Third Parties
  • We rely completely on third parties, including WuXi, to supply drug substance and manufacture drug product for our clinical trials and preclinical studies. We intend to rely on other third parties to produce commercial supplies of product candidates, and our dependence on third parties could adversely impact our business.
  • We have in the past relied and expect to continue to rely on third-party CROs and other third parties to conduct and oversee our research programs, preclinical studies, planned clinical trials and other aspects of product development. If these third parties do not meet our requirements or otherwise operate as required, we may not be able to satisfy our contractual obligations or obtain regulatory approval for, or commercialize, our product candidates when expected or at all.
  • If we enter into collaborations with third parties to develop or commercialize our product candidates, our prospects with respect to those product candidates will depend in significant part on the success of those collaborations.
  • Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.
  • Risks Related to Our Securities
  • The prices of our Common Stock and Warrants may be volatile, and you could lose all or part of your investment.
  • We could be negatively affected as a result of the actions of activists or hostile stockholders.
  • Our Warrants may not have any value.
  • A Warrant does not entitle the holder to any rights as common stockholders until the holder exercises the Warrant for a share of our Common Stock.
  • If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, the price and trading volume of our Common Stock and Warrants could decline.
  • Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.
  • If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading prices of our Common Stock and Warrants.
  • We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Common Stock and Warrants less attractive to investors.
  • The requirements of being a public company may strain our resources, resulting in more litigation and divert management’s attention.
  • We may be subject to securities litigation, which is expensive and could divert management attention.
  • We do not currently intend to pay dividends on our Common Stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our Common Stock.
  • Provisions in our Certificate of Incorporation and Bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our securities.
  • Certain beneficial owners might have control over us which could delay or prevent a change in corporate control or result in the entrenchment of management and/or the Board.
  • Exchange rate fluctuations may materially affect our results of operations and financial condition.
  • Failure to comply with The Nasdaq Capital Market continued listing requirements may result in our Common Stock and/or Warrants being delisted from The Nasdaq Capital Market.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
    SEC EDGAROther events
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54